Extremely Low Hit Rate in a Diverse Chemical Drug Screen Targeting Mycobacterium Abscessus

Overview

Journal Antimicrob Agents Chemother

Publisher American Society for Microbiology

Specialty Pharmacology

Date 2019 Aug 21

PMID 31427298

Citations 13

Authors

Jakob J Malin

Sandra Winter

Edeltraud van Gumpel

Georg Plum

Jan Rybniker

Affiliations

Soon will be listed here.

Citing Articles

Characterization of novel double-reporter strains of for drug discovery: a study in mScarlet.

Bento C, Van Calster K, Piller T, Oliveira G, De Vooght L, Cappoen D Microbiol Spectr. 2024; 12(10):e0036224.

PMID: 39189762 PMC: 11448253. DOI: 10.1128/spectrum.00362-24.

Antimicrobial and Antibiofilm Effects of Bithionol against .

Cao D, Yuan X, Jiang X, Wu T, Xiang Y, Ji Z Antibiotics (Basel). 2024; 13(6).

PMID: 38927195 PMC: 11200778. DOI: 10.3390/antibiotics13060529.

Exploring antibiotic resistance mechanisms in for enhanced therapeutic approaches.

Nguyen T, Heo B, Jeon S, Ash A, Lee H, Moon C Front Microbiol. 2024; 15:1331508.

PMID: 38380095 PMC: 10877060. DOI: 10.3389/fmicb.2024.1331508.

Characterization of Two Novel Inhibitors of the Mycobacterium tuberculosis Cytochrome Complex.

Gries R, Dal Molin M, Chhen J, van Gumpel E, Dreyer V, Niemann S Antimicrob Agents Chemother. 2023; 67(7):e0025123.

PMID: 37358461 PMC: 10353358. DOI: 10.1128/aac.00251-23.

Natural Products Lysobactin and Sorangicin A Show Activity against Mycobacterium abscessus Complex.

Sullivan J, Yao J, Courtine C, Lupien A, Herrmann J, Muller R Microbiol Spectr. 2022; 10(6):e0267222.

PMID: 36342177 PMC: 9769517. DOI: 10.1128/spectrum.02672-22.

References

Le Run E, Arthur M, Mainardi J . and Intracellular Activity of Imipenem Combined with Rifabutin and Avibactam against Mycobacterium abscessus. Antimicrob Agents Chemother. 2018; 62(8). PMC: 6105861. DOI: 10.1128/AAC.00623-18. View

Nessar R, Cambau E, Reyrat J, Murray A, Gicquel B . Mycobacterium abscessus: a new antibiotic nightmare. J Antimicrob Chemother. 2012; 67(4):810-8. DOI: 10.1093/jac/dkr578. View

Manjunatha U, Smith P . Perspective: Challenges and opportunities in TB drug discovery from phenotypic screening. Bioorg Med Chem. 2015; 23(16):5087-97. DOI: 10.1016/j.bmc.2014.12.031. View

Wu M, Aziz D, Dartois V, Dick T . NTM drug discovery: status, gaps and the way forward. Drug Discov Today. 2018; 23(8):1502-1519. PMC: 6078814. DOI: 10.1016/j.drudis.2018.04.001. View

Lechartier B, Rybniker J, Zumla A, Cole S . Tuberculosis drug discovery in the post-post-genomic era. EMBO Mol Med. 2014; 6(2):158-68. PMC: 3927952. DOI: 10.1002/emmm.201201772. View

Aziz D, Low J, Wu M, Gengenbacher M, Teo J, Dartois V . Rifabutin Is Active against Mycobacterium abscessus Complex. Antimicrob Agents Chemother. 2017; 61(6). PMC: 5444174. DOI: 10.1128/AAC.00155-17. View

Herrmann J, Rybniker J, Muller R . Novel and revisited approaches in antituberculosis drug discovery. Curr Opin Biotechnol. 2017; 48:94-101. DOI: 10.1016/j.copbio.2017.03.023. View

Kaushik A, Ammerman N, Martins O, Parrish N, Nuermberger E . Activity of New Tetracycline Analogs Omadacycline and Eravacycline against Drug-Resistant Clinical Isolates of . Antimicrob Agents Chemother. 2019; 63(6). PMC: 6535573. DOI: 10.1128/AAC.00470-19. View

Geiman D, Raghunand T, Agarwal N, Bishai W . Differential gene expression in response to exposure to antimycobacterial agents and other stress conditions among seven Mycobacterium tuberculosis whiB-like genes. Antimicrob Agents Chemother. 2006; 50(8):2836-41. PMC: 1538666. DOI: 10.1128/AAC.00295-06. View

10.

Burian J, Ramon-Garcia S, Howes C, Thompson C . WhiB7, a transcriptional activator that coordinates physiology with intrinsic drug resistance in Mycobacterium tuberculosis. Expert Rev Anti Infect Ther. 2012; 10(9):1037-47. DOI: 10.1586/eri.12.90. View

11.

van Ingen J, Boeree M, van Soolingen D, Mouton J . Resistance mechanisms and drug susceptibility testing of nontuberculous mycobacteria. Drug Resist Updat. 2012; 15(3):149-61. DOI: 10.1016/j.drup.2012.04.001. View

12.

Ekins S, Clark A, Dole K, Gregory K, McNutt A, Spektor A . Data Mining and Computational Modeling of High-Throughput Screening Datasets. Methods Mol Biol. 2018; 1755:197-221. PMC: 6181121. DOI: 10.1007/978-1-4939-7724-6_14. View

13.

Ramon-Garcia S, Ng C, Jensen P, Dosanjh M, Burian J, Morris R . WhiB7, an Fe-S-dependent transcription factor that activates species-specific repertoires of drug resistance determinants in actinobacteria. J Biol Chem. 2013; 288(48):34514-28. PMC: 3843066. DOI: 10.1074/jbc.M113.516385. View

14.

Richter A, Strauch A, Chao J, Ko M, Av-Gay Y . Screening of Preselected Libraries Targeting Mycobacterium abscessus for Drug Discovery. Antimicrob Agents Chemother. 2018; 62(9). PMC: 6125491. DOI: 10.1128/AAC.00828-18. View

15.

Rybniker J, Vocat A, Sala C, Busso P, Pojer F, Benjak A . Lansoprazole is an antituberculous prodrug targeting cytochrome bc1. Nat Commun. 2015; 6:7659. PMC: 4510652. DOI: 10.1038/ncomms8659. View

16.

Griffith D, Eagle G, Thomson R, Aksamit T, Hasegawa N, Morimoto K . Amikacin Liposome Inhalation Suspension for Treatment-Refractory Lung Disease Caused by Complex (CONVERT). A Prospective, Open-Label, Randomized Study. Am J Respir Crit Care Med. 2018; 198(12):1559-1569. DOI: 10.1164/rccm.201807-1318OC. View

17.

Bryant J, Grogono D, Rodriguez-Rincon D, Everall I, Brown K, Moreno P . Emergence and spread of a human-transmissible multidrug-resistant nontuberculous mycobacterium. Science. 2016; 354(6313):751-757. PMC: 5142603. DOI: 10.1126/science.aaf8156. View

18.

Rybniker J, Chen J, Sala C, Hartkoorn R, Vocat A, Benjak A . Anticytolytic screen identifies inhibitors of mycobacterial virulence protein secretion. Cell Host Microbe. 2014; 16(4):538-48. DOI: 10.1016/j.chom.2014.09.008. View

19.

Hurst-Hess K, Rudra P, Ghosh P . Mycobacterium abscessus WhiB7 Regulates a Species-Specific Repertoire of Genes To Confer Extreme Antibiotic Resistance. Antimicrob Agents Chemother. 2017; 61(11). PMC: 5655061. DOI: 10.1128/AAC.01347-17. View

20.

van Ingen J, Totten S, Helstrom N, Heifets L, Boeree M, Daley C . In vitro synergy between clofazimine and amikacin in treatment of nontuberculous mycobacterial disease. Antimicrob Agents Chemother. 2012; 56(12):6324-7. PMC: 3497179. DOI: 10.1128/AAC.01505-12. View